PMID- 36530219
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221222
IS  - 2589-9368 (Electronic)
IS  - 2589-9368 (Linking)
VI  - 16
DP  - 2022 Dec
TI  - The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of 
      type 2 diabetes mellitus and obesity.
PG  - 100220
LID - 10.1016/j.metop.2022.100220 [doi]
LID - 100220
AB  - The ever-increasing burden of obesity, type 2 diabetes mellitus (T2DM) and 
      related comorbidities is demanding a better pathophysiological understanding as 
      well as new treatment options. Incretin based therapies are already available 
      while the recent Food and Drug Administration (FDA) approval of the dual 
      glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide 
      (GIP) receptor agonist tirzepatide appears to revolutionize the treatment of T2DM 
      and obesity. GLP-1 and GIP exert pleiotropic physiological actions, including 
      enhancement of insulin secretion, glycemic and appetite control, 
      cardioprotection, and adipose tissue improved function among others. Evidence 
      from recent clinical trials has shown that tirzepatide is at least or more 
      effective compared to classic metabolic therapeutic agents, including insulin, 
      when it comes to glycemic control in T2DM. Of importance, it also exerts 
      remarkable weight-lowering actions, emerging as an alternative to bariatric 
      surgery for obesity treatment. Overall, current data show that tirzepatide is a 
      highly effective therapeutic option for T2DM. Numerous ongoing randomized 
      controlled clinical trials are further examining its potential as a treatment for 
      obesity.
CI  - (c) 2022 The Authors. Published by Elsevier Inc.
FAU - Lempesis, Ioannis G
AU  - Lempesis IG
AD  - Institute of Metabolism and Systems Research (IMSR), College of Medical and 
      Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
AD  - Department of Human Biology, NUTRIM School of Nutrition and Translational 
      Research in Metabolism, Maastricht University Medical Centre, Maastricht, The 
      Netherlands, Maastricht, the Netherlands.
FAU - Liu, Junli
AU  - Liu J
AD  - Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University 
      Affiliated 6th People's Hospital, Shanghai Diabetes Institute, Shanghai, China.
FAU - Dalamaga, Maria
AU  - Dalamaga M
AD  - Department of Biologic Chemistry, School of Medicine, National and Kapodistrian 
      University of Athens, Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221205
PL  - England
TA  - Metabol Open
JT  - Metabolism open
JID - 101767753
PMC - PMC9747662
OTO - NOTNLM
OT  - Clinical trials
OT  - Diabetes
OT  - GIP
OT  - GLP-1
OT  - Gut hormone
OT  - Incretin
OT  - Obesity
OT  - Treatment
COIS- None.
EDAT- 2022/12/20 06:00
MHDA- 2022/12/20 06:01
PMCR- 2022/12/05
CRDT- 2022/12/19 03:25
PHST- 2022/12/01 00:00 [received]
PHST- 2022/12/04 00:00 [accepted]
PHST- 2022/12/19 03:25 [entrez]
PHST- 2022/12/20 06:00 [pubmed]
PHST- 2022/12/20 06:01 [medline]
PHST- 2022/12/05 00:00 [pmc-release]
AID - S2589-9368(22)00058-5 [pii]
AID - 100220 [pii]
AID - 10.1016/j.metop.2022.100220 [doi]
PST - epublish
SO  - Metabol Open. 2022 Dec 5;16:100220. doi: 10.1016/j.metop.2022.100220. eCollection 
      2022 Dec.